Boan Biotech Reports the Completion of Patient Enrolment in the P-III Clinical Trial of BA5101, a Proposed Biosimilar Dulaglutide
Shots:
- The patient enrolment has been completed in the P-III trial evaluating BA5101, its proposed biosimilar to Eli Lilly’s Trulicity (dulaglutide) in patients with insufficiently controlled type 2 diabetes mellitus
- The P-I trial in China showed that BA5101 was highly similar PK characteristics, safety & immunogenicity with Trulicity indicating that it has clinical similarity with the reference product & the results were published in the Journal of Expert Opinion on Biological Therapy, Taylor & Francis
- In preclinical studies, BA5101 was found to be highly similar to Trulicity in terms of biological activities & physicochemical properties. BA5101 is used for glycemic control in adults with insufficiently controlled T2D
Ref: PRNewswire | Image: Boan Biotech
Related News:- Dr. Reddy Reports the Completion of the P-I Study of DRL_TC, a Proposed Biosimilar of Tocilizumab for Rheumatoid Arthritis
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
